Clinical trials: Recurrent High Grade Glioma
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
This phase II trial studies how well bendamustine hydrochloride works in treating patients with anaplastic glioma or glioblastoma that has come back (recurrent) or growing, spreading or getting worse (progressive).
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT00823797
- Testing
- Bendamustine Hydrochloride, Quality-of-Life Assessment
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Washington
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
This phase I trial studies the side effects of vaccine therapy when given together with sargramostim in treating patients with malignant glioma.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Giant Cell Glioblastoma
- Trial name
- NCT01250470
- Testing
- Laboratory Biomarker Analysis, Montanide ISA-51/Survivin Peptide Vaccine, Sargramostim
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
This phase I trial is studying the side effects and best dose of ispinesib in treating young patients with relapsed or refractory solid tumors or lymphoma.
- Conditions
- Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma
- Trial name
- NCT00363272
- Testing
- ispinesib, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Newly Diagnosed Pediatric Pontine Glioma, Newly Diagnosed Pediatric High Grade Glioma
A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric Gliomas
The overall objective of this pilot study is to collect immunological and safety data following administration of vaccinations with HLA-A2. This data will be used to decide whether a larger study of clinical efficacy is warranted.
- Conditions
- Newly Diagnosed Pediatric Pontine Glioma, Newly Diagnosed Pediatric High Grade Glioma, Recurrent Pediatric High Grade Glioma, Recurrent Pediatric Low Grade Glioma
- Trial name
- NCT01130077
- Testing
- HLA-A2 restricted glioma antigen peptides vaccine, Poly-ICLC
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- James Felker
Brain and Central Nervous System Tumors
Biological Therapy in Treating Patients With Primary or Advanced Glioma
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells in patients with primary or…
- Trial name
- NCT00003067
- Testing
- aldesleukin, lymphokine-activated killer cells
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Glioma
Evaluation of Clinical Efficacy and Safety of Specific Mode Electroacupuncture Stimulation for Paclitaxel Across BBB Delivery in Patients With Postoperative Recurrence of Malignant Glioma: A Single-arm Trial
Gliomas are the most common type of primary brain tumors, with the main treatment modalities including surgery, radiotherapy, and chemotherapy.
- Trial name
- NCT06818331
- Testing
- SMES+PTX, Paclitaxel, Specific mode electroacupuncture stimulation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Third Affiliated hospital of Zhejiang Chinese Medical University
Recurrent Malignant Glioma
A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I)
This is a phase I study to evaluate the safety and tolerability of IL13Rα2 Targeted Chimeric Antigen Receptor-T Cell in patients with Refractory or Recurrent Malignant Glioma and to evaluate the changes of AE incidence.
- Trial name
- NCT05540873
- Testing
- YYB-103
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- CellabMED
Recurrent GBM
A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma
Cerebraca Wafer (75 mg [(Z)-n-butylidenephthalide]) is designed for surgical combination to treat glioblastoma (GBM) diseases. High-grade glioma includes GBM (Grade IV, isocitrate dehydrogenase 1 [IDH1] wild-type) and anaplastic…
- Trial name
- NCT03234595
- Testing
- Cerebraca wafer
- Where
- 3 sites in Taiwan
- Volunteers
- 22 people
- Sponsor
- Everfront Biotech Co., Ltd.
Malignant Gliomas
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
The goal of this clinical research study is to find the highest tolerable dose of lenalidomide combined with Camptosar (irinotecan) as well as to see if this drug combination can help control malignant gliomas.
- Trial name
- NCT00671801
- Testing
- Irinotecan, Lenalidomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Glioma
Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas
Optico-chiasmatic gliomas have therapeutic feature since surgical resection plays a secondary role. Unlike other sites, many of these tumors are not amenable to complete resection either because of anatomical location, and…
- Trial name
- FLUVABREX (NCT02115074)
- Testing
- Fluvastatine, Celebrex
- Where
- 8 sites in France
- Volunteers
- 20 people
- Sponsor
- Centre Oscar Lambret
Glioblastoma Multiforme, Anaplastic Astrocytoma
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
This study will offer a safe treatment for patients with relapsing recurring glioblastoma (GBM) or anaplastic astrocytoma (AA). The trial will test the hypothesis that Erlotinib (Tarceva, OSI-774) can be safely used up to a dose…
- Trial name
- NCT00301418
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Malignant Glioma, Glioblastoma
Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)
A Phase I, open-label, non-randomized, sequential dose escalation cohort trial of the safety, tolerability, and maximum tolerated dose (MTD) of AP23573 when administered intravenously as a 30-minute infusion, once daily for five…
- Conditions
- Malignant Glioma, Glioblastoma, Gliosarcoma
- Trial name
- NCT00087451
- Testing
- AP23573
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
Brain Metastases, Lung Cancer
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) of 2B3-101 both as single agent and in combination with trastuzumab.
- Conditions
- Brain Metastases, Lung Cancer, Breast Cancer, Melanoma
- Trial name
- NCT01386580
- Testing
- 2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks
- Where
- 10 sites in United States, Belgium and 2 more
- Volunteers
- 84 people
- Sponsor
- BBB-Therapeutics B.V.
Currently Only Enrolling Glioblastoma Patients at First Recurrence
Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas
This phase I trial studies the safety of giving multiple intracerebral doses of NSC-CRAd-S-pk7 to treat patients with glioblastoma at first recurrence.
- Trial name
- NCT05139056
- Testing
- Neural Stem Cells-expressing CRAd-S-pk7, Resection
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center
High Grade Glioma
Low Dose Radiation Therapy for Glioblastoma Multiforme
To evaluate the safety and effectiveness of low dose rate radiation therapy plus temozolomide. This will be in patients with High Grade Glioma (to only include Anaplastic Astrocytoma or Glioblastoma Multiforme) who have…
- Trial name
- NCT01466686
- Testing
- Low Dose Fractionated Radiation Therapy (LDFRT), Temozolomide
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma, Gliosarcoma
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Primary objective: To estimate 6-month progression free survival probability of pts w recurrent malignant gliomas treated w erlotinib + bevacizumab.
- Trial name
- NCT00671970
- Testing
- Bevacizumab and Erlotinib
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Duke University
Recurrent Malignant Glioma, Glioblastoma Multiforme of Brain
Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)
The purpose of this study is to determine how safe and how well-tolerated the experimental study drug, C134 is when re-administered into the brain where the tumor is located.
- Conditions
- Recurrent Malignant Glioma, Glioblastoma Multiforme of Brain, Gliosarcoma of Brain, Anaplastic Astrocytoma of Brain
- Trial name
- NCT06193174
- Testing
- C134 Re-Administration
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Alabama at Birmingham
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well palbociclib works in treating patients with Rb positive solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations (mutations) in cell cycle genes…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma
- Trial name
- NCT03526250
- Testing
- Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
- Where
- 117 sites in United States, Puerto Rico
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Glioma of Brain
Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma
The purpose of this study is to determine if treatment with Topotecan by an alternative method, delivering topotecan directly into brain tumors, is safe and well tolerated.
- Trial name
- NCT03927274
- Testing
- Topotecan
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Glioblastoma Multiforme, Anaplastic Astrocytoma
Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor
This is a multicenter study evaluating the safety and tolerability of increasing doses of Toca 511, a retroviral replicating vector, injected into the resection cavity of patients with Grade III or Grade IV Gliomas who have…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
- Trial name
- NCT01470794
- Testing
- Toca 511 vector, Toca FC
- Where
- 8 sites in United States
- Volunteers
- 58 people
- Sponsor
- Tocagen Inc.